The ENA Profile test evaluates antibodies against various nuclear antigens to aid in diagnosing autoimmune diseases like lupus and scleroderma. It offers comprehensive screening for multiple autoantibodies, guiding clinicians in disease identification and management decisions. Results help assess autoimmune disease activity and tailor treatment strategies.

The ENA Profile test aids in diagnosing autoimmune diseases by detecting antibodies against specific nuclear antigens. Risks associated with the test are minimal, primarily involving slight discomfort or bruising at the blood draw site. False positives or negatives are possible, requiring clinical correlation for accurate diagnosis and management.

The ENA Profile test typically provides qualitative results, indicating the presence or absence of specific autoantibodies against nuclear antigens. There are no standardized quantitative ranges for this test. Interpretation relies on the presence or absence of autoantibodies, aiding in the diagnosis and classification of autoimmune diseases. Additional tests and clinical correlation may be necessary for definitive diagnosis and management.

Interpretation of the ENA Profile test involves assessing the presence or absence of specific autoantibodies against nuclear antigens. Positive results indicate the presence of autoantibodies associated with autoimmune diseases, aiding in diagnosis and classification. Negative results suggest the absence of these autoantibodies but do not exclude autoimmune diseases, necessitating clinical correlation for accurate diagnosis and management.